- Visibility 281 Views
- Downloads 23 Downloads
Comparison of efficacy of olopatadine hydrochloride 0.1% and azelastine hydrochloride 0.05% eye drops for treatment of allergic conjunctivitis in rural South India
- Author Details:
-
Vijay Kumar Srivastava
-
Kunal Verma
Introduction: Conjunctival inflammation due to allergy is known as allergic conjunctivitis. Common ocular symptoms may be itching, swelling of eyelids, watering, watery discharge, photophobia and foreign body sensation.
Aims and Objectives: To Compare the efficacy of Olopatadine Hydrochloride 0.1% and Azelastine Hydrochloride 0.05% Eye drops for Treatment of Allergic Conjunctivitis in Rural South India.
Methodology: A prospective clinical trial in 74 patients was carried out. Patients by random selection were given treatment by Olopatadine Hydrochloride 0.1% and Azelastine Hydrochloride 0.05% eye drops. Patients were assessed by ophthalmologist 0, 3rd, 7th and 14th day after starting treatment. During visits the symptom were graded from zero to three scale.
Result: The mean age in Olopatadine group was 18± 3.6 years and in Azelastine group was 19± 4.4 years. There were 26 Males and 11 Females in Olopatadine group and 28 Males and 9 Females in Azelastine group. The mean values for the duration of disease in both the groups were 2.8± 2.2 months and 2.9± 2.4 months respectively in Olopatadine and Azelastine group. The symptoms were compared in the two groups on 3rd, 7th and 14th day after starting treatment. The score given by the Ophthalmologist were markedly lower in both groups after treatment during all visits. (P<0.05).
Conclusion: Both Olopatadine and Azelastine reduced symptoms of allergic conjunctivitis very significantly however Olopatadine was more effective.
Keywords: Allergic Conjunctivitis, Olopatadine Hydrochloride, Azelastine Hydrochloride
References
- Chigbu DI. The pathophysiology of ocular allergy: A review. Cont Lens Anterior Eye 32:3–15; quiz 43–44,
- [PubMed]
- Bielory L, Meltzer EO, Nichols KK, et al. An algorithm for the management of allergic conjunctivitis. Allergy Asthma Proc 34:408–420, 2013. [PubMed]
- Allansmith M.R., Ross R.N. (1991). "Phlyctenular keratoconjunctivitis". In Tasman W., Jaeger E.A. Duane's Clinical Ophthalmology 1 (revised ed.). Philadelphia: Harper & Row. pp. 1–5.
- "Conjunctivitis (inflammation of the eye)". netdoctor.co.uk. Archived from the original on 15 April
- Retrieved 2010-04-06.
- Leonardi A. The central role of conjunctival mast cells in the pathogenesis of ocular allergy. Curr Allergy Asthma Rep 2:325–331,2002. [PubMed]
- Alexander M, Berger W, Buchholz P. The reliability, validity, and preliminary responsiveness of the Eye Allergy Patient Impact Questionnaire (EAPIQ). Health Qual Life Outcomes 2005;3:67.
- Gelardi M, Leo ME, Quaranta VN, et al. Clinical characteristics associated with conjunctival inflammation in allergic rhinoconjunctivitis. J Allergy Clin Immunol Pract 3:387–391.e1, 2015. [PubMed]
- Bielory L, Friedlaender MH. Allergic conjunctivitis. Immunol Allergy Clin North Am 2008;28:43-58.
- Pitt AD, Smith AF, Lindsell L, et al. Economic and quality-of-life impact of seasonal allergic conjunctivitis in Oxfordshire. Ophthalmic Epidemiol 11:17–33,2004. [PubMed]
- Smith AF, Pitt AD, Rodruiguez AE, et al. The economic and quality of life impact of seasonal allergic conjunctivitis in a Spanish setting. Ophthalmic Epidemiol 12:233–242,2005. [PubMed]
- Ray NF, Baraniuk JN, Thamer M. Direct expenditures for the treatment of allergic rhinoconjunctivitis in 1996, including the contributions of related airway illnesses. J Allergy Clin Immunol 1999;103:401-7.
- Calderon MA, Penagos M, Sheikh A, et al. Sublingual immunotherapy for allergic conjunctivitis: Cochrane systematic review and meta-analysis. Clin Exp Allergy 41:1263–1272,2011. [PubMed]
- Bielory L. Ocular allergy guidelines: A practical treatment algorithm. Drugs 2002;62:1611-34.
- Lin SY, Erekosima N, Kim JM, et al. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: A systematic review. JAMA 309:1278–1288,2013. [PubMed]
- El Hennawi M. A double blind placebo controlled group comparison study of ophthalmic sodium cromoglycate and nidocromil sodium in the treatment of vernal keratoconjunctivitis. Br J Ophthalmol.1994;78:365.
- Tinkelman DG, Rupp G, Kaufman H, Pugely J, Schultz N. Doublemasked, paired-comparison clinical study of ketorolac tromethamine 0.5% ophthalmic solution compared with placebo eye drops in the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol 1993;38(Suppl):133-40.
- Ballas Z, Blumenthal M, Tinkelman DG, Kriz R, Rupp G. Clinical evaluation of ketorolac tromethamine 0.5% ophthalmic solution for the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol 1993;38(Suppl):141-8
- Blaiss MS, Dykewicz MS, Skoner DP, et al. Diagnosis and treatment of nasal and ocular allergies: The Allergies, Immunotherapy, and RhinoconjunctivitiS (AIRS) surveys. Ann Allergy Asthma Immunol 2014;112:322–
- e321,2014. [PubMed]
- Joss J, Craig T. Seasonal allergic conjuctivitis. Drugs Today (Barc) 1998;34:259-65.
- Berdy GJ, Hedquest B. Ocular allergic disorders and dry eye disease. Associations, diagnostic dilemma and management. Acta Ophthalmol Scand 2000;78:32-7.
- Manzouri B, Thomas HF, Larkin F, Ono SJ, Wyser R. Pharmacotherapy allergic eye disease. Expert Opin Pharmacother 2006;79:1191-200.
- Spangler DL, Bensch G, Berdy GJ. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model. Clin Ther. 2001 Aug;23(8):1272-80.
- Singh K, Bielory L, Hackensack NJ, Newark NJ: Epidemiology of ocular allergy symptoms in United States adults (1988-1994). Ann Allergy Asthma Immunol. 2007;98:34-A22.
- Bonini S. Allergic conjunctivitis: the forgotten disease. Chem Immunol Allerg. 2006;91:110-20.
- Singh K, Bielory L, Hackensack NJ, Newark NJ. Ocular allergy: a national epidemilogic study. J Allergy Clin Immunol. 2007;119(Suppl 1):S154.
- Takano Y, Narita S, Kobayashi K. Seasonal allergic rhinitis in Hakodote. Nippon Ganka Gakkai Zasshi. 2004;108:606-11.
- Liu RF, Wu XX, Wang X, Gao J, Zhou J, Zhao Q. Efficacy of olopatadine hydrochloride 0.1%, emedastine difumarate 0.05%, and loteprednol etabonate 0.5% for Chinese children with seasonal allergic conjunctivitis: a randomized vehicle-controlled study. Int Forum Allergy Rhinol. 2016 Nov 21. doi: 10.1002/alr.21882
[Google Scholar] [Epub ahead of print] - Polansky JR. Side effects of topical therapy with anti- inflammatory steroids. Curr Opin Ophthalmol 1992;3:259-72.
How to Cite This Article
Vancouver
Srivastava VK, Verma K. Comparison of efficacy of olopatadine hydrochloride 0.1% and azelastine hydrochloride 0.05% eye drops for treatment of allergic conjunctivitis in rural South India [Internet]. Indian J Clin Exp Ophthalmol. 2017 [cited 2025 Oct 06];3(2):207-209. Available from: https://doi.org/
APA
Srivastava, V. K., Verma, K. (2017). Comparison of efficacy of olopatadine hydrochloride 0.1% and azelastine hydrochloride 0.05% eye drops for treatment of allergic conjunctivitis in rural South India. Indian J Clin Exp Ophthalmol, 3(2), 207-209. https://doi.org/
MLA
Srivastava, Vijay Kumar, Verma, Kunal. "Comparison of efficacy of olopatadine hydrochloride 0.1% and azelastine hydrochloride 0.05% eye drops for treatment of allergic conjunctivitis in rural South India." Indian J Clin Exp Ophthalmol, vol. 3, no. 2, 2017, pp. 207-209. https://doi.org/
Chicago
Srivastava, V. K., Verma, K.. "Comparison of efficacy of olopatadine hydrochloride 0.1% and azelastine hydrochloride 0.05% eye drops for treatment of allergic conjunctivitis in rural South India." Indian J Clin Exp Ophthalmol 3, no. 2 (2017): 207-209. https://doi.org/